albumin-bound paclitaxel / Generic mfg. - LARVOL DELTA

De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial. (ASCO 2025) - P3 | "Patients were stratified by nodal and hormone receptor status and randomized (1:1) to receive six 3-week cycles of an investigator-selected taxane (docetaxel, paclitaxel or nab-paclitaxel) plus trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) and pertuzumab (840 mg loading dose, then 420 mg every 3 weeks), with carboplatin (TCbHP; AUC 6 mg/mL per min) or without carboplatin (THP). THP provided non-inferior pCR rates and improved tolerability compared with TCbHP. Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer."

Clinical • Late-breaking abstract • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Leukopenia • Neutropenia • Oncology • Solid Tumor • HER-2

Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. (ASCO 2025) - P3 | " Patients were randomized 1:1 to SG (10 mg/kg IV, day 1 & 8) + pembro (200 mg, day 1, max 35 cycles) in 21-day cycles or chemo (gemcitabine + carboplatin, paclitaxel, nab-paclitaxel) + pembro until disease progression or unacceptable toxicity. SG + pembro led to a statistically significant and clinically meaningful improvement in PFS vs chemo + pembro with durable responses, no new safety concerns for SG or pembro, and a lower rate of treatment discontinuation due to TEAEs in patients with previously untreated, PD-L1–positive advanced TNBC. These data support the use of SG + pembro as a potential new standard of care treatment in this patient population."

Clinical • Late-breaking abstract • Metastases • P3 data • Anemia • Breast Cancer • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer • PD-L1

Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. (PubMed, Nat Commun) - P | "The COMPASS trial (NCT02750657) enrolled 268 patients with advanced PDAC; patients were given either modified (m) FOLFIRINOX or Gemcitabine-nab-paclitaxel (GnP) as per physicians choice...Basal-like PDAC and patients exhibiting evidence of systemic inflammation as annotated using the Gustave Roussy Immune Score are unique poor prognostic cohorts. The latter associates with low CD8 T cell infiltration while basal-like PDAC documents an inflamed tumour microenvironment."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD8 • HRD • KRAS

Tislelizumab Plus Chemotherapy Followed by Surgery or Radiotherapy and Adjuvant Tislelizumab in Unresectable Stage III NSCLC (IASLC-WCLC 2025) - "Patients received 2-4 cycles of induction TIS plus nab-paclitaxel and platinum. A notable proportion of patients were enabled to receive radical surgery and attained good pathological response. Recruitment is ongoing, and efficacy and safety will be continuously monitored."

Clinical • Surgery • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. (PubMed, J Clin Oncol) - "In the phase II Pancreatic Adenocarcinoma Signature Stratification for Treatment-01 (PASS-01) trial population, PFS was similar between GnP and mFFX; however, OS and safety trends favored GnP. The second-line setting appears inadequate to offer precision choices, given the short survival observed."

Journal • P2 data • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • BRCA1 • BRCA2 • PALB2

Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i) (ESMO 2025) - P3 | "Background Significant PFS benefit was observed with SG vs chemo in pretreated metastatic (m)TNBC (ASCENT) and with SG + pembrolizumab vs chemo + pembrolizumab in first-line (1L) PD-L1+ mTNBC (ASCENT-04)...Randomization (1:1) to SG (10 mg/kg IV, days 1 & 8 in 21-day cycles) or chemo (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) was stratified by disease status and geography...These data support SG as a potential new standard of care for pts with previously untreated mTNBC who are unable to receive a PD-(L)1i. Table: LBA20 Efficacy: Intent-to-treat SG (n = 279) Chemo (n = 279) Median PFS per BICR (95% CI), mo 9.7 (8.2-11.1) 6.9 (5.6-8.3) HR (95% CI); adjusted two-sided P -value 0.62 (0.50-0.78); P < .0001 ORR (95% CI), % 48.4 (42.4-54.4) 45.5 (39.6-51.6) Median DOR (95% CI), mo 12.2 (9.7-13.8) 7.2 (5.7-8.4) Safety: All treated n = 275 n = 276 TEAEs, n (%) Any grade Grade ≥ 3 Led to dose reduction Led to treatment discontinuation 273 (99) 181 (66)..."

Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1

VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC) (ESMO 2025) - P2 | "Conclusions This study met its primary endpoints. Patients receiving VCN-01 + GA had improved OS, PFS and DoR compared to GA SoC."

Clinical • Metastases • P2b data • Oncology • Pancreatic Cancer • Solid Tumor • CA 19-9

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial (ESMO 2025) - P1, P3 | "Methods Adult pts with previously untreated locally recurrent inoperable or mTNBC, for whom immunotherapy was not an option, were randomised 1:1 to Dato-DXd (6 mg/kg IV Q3W) or investigator's choice of chemotherapy (ICC; [nab]-paclitaxel/ capecitabine/ eribulin mesylate/ carboplatin). The Dato-DXd safety profile was manageable. Results support Dato-DXd as the new 1L standard of care."

Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1

Nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous NSCLC and untreated brain metastases (CA209-7WF/Break B5-BM-NSCLC/AIO-TRK-0220/ass) (ESMO 2025) - P2 | "Pts received nivolumab (360 mg, q3w), ipilimumab (1 mg/kg, q6w) and bevacizumab (400 mg, q3w) concomitantly with 2 cycles of chemotherapy [carboplatin (AUC 5, q3w) plus nab-paclitaxel (100 mg/m 2 , q1w)]. Most common adverse events grade ≥ 3 were pneumonia (6 pts), neutropenia (5 pts), alanine aminotransferase increased (4 pts), acute kidney injury (3 pts), sepsis (3 pts) and infection (3 pts). Conclusions The Break-B5 trial demonstrated promising intracranial activity in active (asymptomatic + symptomatic) BMs of NSCLC along with a manageable safety profile."

Clinical • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D mutant advanced pancreatic cancer: A phase Ib/II study (ESMO 2025) - P1/2 | "Conclusions HRS-4642 combined with GA showed encouraging antitumor activity and manageable safety profile in advanced KRAS -G12D mutant PDAC. Follow-up is ongoing for long-term efficacy and safety data."

IO biomarker • Metastases • P1/2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

Phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC) (ESMO 2025) - P1 | "Table: 2214MO Outcome Overall (N=42 ‡ ) 1L FOLFIRINOX (n=26) 1L gem– nab -paclitaxel (n=15) Best overall response,* ,† n (%) CR 0 0 0 PR 10 (24) 4 (15) 6 (40) SD 24 (57) 17 (65) 6 (40) PD 4 (10) 2 (8) 2 (13) NE/Not assessed 4 (10) 3 (12) 1 (7) ORR,* ,† n (%) 10 (24) 4 (15) 6 (40) CBR,* ,† n (%) 34 (81) 21 (81) 12 (80) Median PFS, mo [95% CI] 5.3 [4.0, 6.8] 5.0 [3.6, 6.2] 6.8 [2.4, NE] *Confirmed responses...CBR, clinical benefit rate; CR, complete response; NE, not estimable; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease. Conclusions Temab-A had a manageable safety profile in pts with advanced PDAC and promising efficacy, especially in pts who received 1L gemcitabine– nab -paclitaxel."

Clinical • P1 data • Pan tumor • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • MET

PHASE 3 ROSELLA (GOG-3073, ENGOT-OV72) TRIAL OF RELACORILANT + NAB-PACLITAXEL VS NAB-PACLITAXEL IN PLATINUM-RESISTANT OVARIAN CANCER: PRIMARY RESULTS AND OUTCOMES IN OLDER PATIENTS (IGCS 2025) - "The addition of relacorilant to nab-paclitaxel showed a statistically significant improvement in PFS by BICR and a clinically meaningful benefit in OS at the interim analysis (Table). Patients aged ≥65 were heavily pretreated, had advanced disease, and were similarly distributed between treatment arms (38.3% vs 41.5%). The addition of relacorilant was associated with a 39% reduction in the risk of progression in this subgroup (PFS by BICR: HR 0.61 [95% CI 0.40-0.94] P=0.0247)."

Clinical • Late-breaking abstract • P3 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07 (SABCS 2025) - P3 | " Participants were randomized 2:1 to receive SG 10 mg/kg IV or chemotherapy treatment of physician's choice (TPC; capecitabine, nab-paclitaxel, or paclitaxel). The study did not meet the primary endpoint of PFS by BICR in participants with HR+/HER2−, locally advanced unresectable or mBC who have received prior ET and are candidates for first chemotherapy. No new safety concerns were identified. An early trend in improvement of OS was observed, and the study will continue to further assess OS."

Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer. (PubMed, Nat Commun) - "Here, we analyze pre-, on-, and post-treatment biopsies from 20 female patients with stage II-III HR+ breast cancer who participated in a clinical trial of neoadjuvant chemo-immunotherapy with nab-paclitaxel and pembrolizumab. Unfavorable responders demonstrate increased tumor estrogen signaling and immunosuppressive tumor-immune interactions. In this work, we highlight the interplay between tumor and microenvironmental cells in treatment naïve and exposed HR+ breast cancers and reveal that pivotal shifts in tumor cell, macrophage, and T cell states may mediate response to chemo-immunotherapy."

IO biomarker • Journal • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC): early safety and efficacy results in participants (pts) from Asia (ESMO Asia 2025) - P3 | "We report early safety and efficacy data within a subgroup of pts from Asia. Pts receive D 1500 mg (first infusion: 60 min; subsequent infusions: 30 min) with an investigator-selected G-based chemotherapy (D + G alone or in combination with oxaliplatin [O], carboplatin [C], cisplatin [cis], tegafur-gimeracil-oteracil [S-1], cis + S-1, or cis + nab-paclitaxel [P]). In pts from Asia, the safety profiles of all study tx were manageable. Safety results for pts from Asia were comparable to the global TOURMALINE population and TOPAZ-1 study. Interim ORR is promising."

Clinical • Combination therapy • Metastases • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Trial in progress: A phase 2/3 trial of iza-bren (BMS986507/BL-B01D1), an EGFRxHER3 antibody-drug conjugate, vs standard-of-care chemotherapy in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple negative breast cancer ineligible for anti-PD-(L)1 treatment (IZABRIGHT-Breast01) (SABCS 2025) - P2/3 | " IZABRIGHT-Breast01 (NCT06926868) is an open-label, randomized phase 2/3 trial evaluating the efficacy and safety of iza-bren vs chemotherapy of investigator's choice (paclitaxel, nab-paclitaxel, capecitabine, or carboplatin plus gemcitabine) in patients with previously untreated, locally advanced, recurrent inoperable or metastatic TNBC or estrogen receptor (ER)-low, HER2-negative BC who are ineligible for approved anti-programmed death-1/programmed death ligand 1 (PD-[L]1)-based treatment combinations or endocrine therapy-based treatments, respectively. The key secondary endpoint is overall survival. Other secondary endpoints include investigator-assessed PFS, objective response, disease control rate, duration of response, time to response, time to subsequent treatment, PFS after next line of treatment, safety, and health-related quality of life."

Clinical • Metastases • P2/3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • BRCA2 • ER • HER-2 • PGR

Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). (ASCO-GI 2026) - P1/2 | "Overall, spevatamig + GnP is well tolerated, with no significant additive toxicity to GnP. Spevatamig + GnP showed promising efficacy when compared with published studies of GnP in 1L mPDAC, suggesting that spevatamig + GnP may provide additional clinical benefit to patients."

Combination therapy • Metastases • P1/2 data • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CLDN18

Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results. (ASCO-GI 2026) - P1/2 | "Narmafotinib combined with Gem/NabP was associated with manageable toxicity and the P2a study met its primary efficacy endpoint. OS data is awaited and further studies are planned."

Clinical • Combination therapy • Metastases • P2a data • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK-3 inhibitor elraglusib and gemcitabine/nab-paclitaxel in the 1801 Part 3B phase 2 study. (ASCO-GI 2026) - P2 | "Our preliminary results identified KRAS and TP53 gene mutations as potential predictive biomarkers of clinical outcome in elraglusib/GnP-treated mPDAC patients. Updated OS data and mutational analysis will be included in the final presentation."

Biomarker • Clinical • Metastases • P2 data • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • CDKN2A • KRAS • TP53

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. (PubMed, J Clin Oncol) - "THP provided noninferior pCR rates and improved tolerability compared with TCbHP. Omitting carboplatin may be applicable in HER2-positive breast cancer."

Head-to-Head • Journal • P3 data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Leukopenia • Neutropenia • Oncology • Solid Tumor • HER-2

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. (PubMed, Nat Commun) - P2 | "In this phase 2 study (NCT05047991), patients with unresectable metastatic pancreatic adenocarcinoma were randomized to receive NALIRIFOX (liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin) or gemcitabine plus nab-paclitaxel...≥ Grade 3 treatment-emergent adverse events (TEAEs) occurred in 73.1% of patients receiving NALIRIFOX and 84.6% of patients receiving gemcitabine plus nab-paclitaxel, respectively. Despite the premature termination (predetermined sample size of n = 153 not reached) of the study, NALIRIFOX demonstrated improvement in PFS compared with gemcitabine plus nab-paclitaxel, with a manageable safety profile in Chinese patients with advanced pancreatic adenocarcinoma."

Journal • P2 data • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • UGT1A1

A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT (clinicaltrials.gov) - P3 | N=378 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

New P3 trial • Cervical Cancer • Oncology • Solid Tumor

Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A). (PubMed, BMC Cancer) - No abstract available

Journal • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

An Unusual Case of Nab-Paclitaxel Induced Allergic Reaction In A Paclitaxel-Sensitive Patient (AAAAI 2026) - "Severe reactions are managed with desensitization or switching to alternatives such as nab-paclitaxel. We report an unusual case of HSRs to both paclitaxel and nab-paclitaxel."

Clinical • Allergy • Immunology

Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article. (PubMed, Biomedicines) - "The median survival time for metastatic patients treated with FOLFIRINOX chemotherapy is 11 months, compared to 8.5 months for patients treated with gemcitabine and nab-paclitaxel-based chemotherapy. Olaparib in the maintenance treatment of patients with advanced pancreatic cancer prolongs the time to progression compared to placebo but does not affect median overall survival. Immunotherapy and targeted therapy have so far been used in a narrow group of patients with a specific molecular profile, but further research on this cancer offers a real opportunity to develop new treatment approaches. This review article is based on the NCCN (National Comprehensive Cancer Network) guidelines and publications available in the PubMed database."

Journal • Review • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor